



## OGT Introduces New Array CGH Interpretation Software

*CytoSure™ Interpret offers complete data integration and rapid analysis workflows for more meaningful results*



IMAGE: OGT CytoSure Interpret software - Automated aberration detection with CytoSure analysis software, showing clear detection of chromosomal abnormalities

*For a high resolution image please contact [neilr@alto-marketing.com](mailto:neilr@alto-marketing.com)*

**Oxford, UK – 10<sup>th</sup> December 2009.** Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has introduced its new CytoSure™ Interpret software, for faster and easier translation of oligo aCGH data into meaningful results. This new release builds on OGT's previous software package with the addition of significant functionality such as the 'Accelerate' workflow, for speeding-up and streamlining the analysis and interpretation of aCGH data. Developed through consultation with users, CytoSure Interpret ensures that cytogeneticists and molecular biologists benefit from highly flexible workflows and in-depth contextual information for clearer data interpretation.

Dr. Agne Liedén from the Department of Molecular Medicine and Surgery, Karolinska Institutet commented: "I am extremely impressed with the ease-of-use and flexibility of the new CytoSure Interpret software. The main highlight for me is that I can include data from our own results, multiple annotation tracks for known CNVs from all major sources, as well as the population analysis tool."

The CytoSure Interpret 'Accelerate' function enables the automation of data analysis workflows, minimising the need for user intervention and maximising the consistency and speed of data interpretation. Users are able to tailor the software to their needs, customising numerous functions including normalisation, aberration detection and report generation. Importantly, CytoSure Interpret provides comprehensive contextual input by fully integrating results with legacy data, confirmation probe information (including FISH and MLPA), as well as extensive annotation tracks covering syndromes, genes, exons, CNVs and recombination



hotspots. Furthermore, these link to publicly available databases such as Decipher and the Database of Genomic Variants to provide even greater context.

James Clough, Commercial Director at OGT, stated: “The advanced functionality of CytoSure Interpret is a result of our ongoing and extremely valuable discussions with our users. We believe that CytoSure Interpret offers a step-change in the analysis and interpretation of aCGH data, enabling researchers to handle large volumes of data to move our understanding forward.”

In addition to this advanced interpretation software, the OGT CytoSure aCGH product line includes a range of high quality arrays covering single disorders through to entire syndrome spreads, as well as SciGene automation instrumentation (now distributed in Europe by OGT). As a result, OGT’s comprehensive products and services are the ideal solution for running oligo aCGH in the laboratory.

For further information on OGT products and services please visit <http://www.ogt.co.uk>.

**For further information, please contact:**

Oxford Gene Technology, Begbroke Science Park,  
Sandy Lane, Yarnton, Oxford OX5 1PF

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: [products@ogt.co.uk](mailto:products@ogt.co.uk)

W: [www.ogt.co.uk](http://www.ogt.co.uk)

**About Oxford Gene Technology**

Founded in 1995 by Professor Ed Southern, OGT has a proven pedigree in microarray technology and services. Our mission is to advance molecular medicine through pioneering discovery and application of molecular technologies. OGT’s key focus areas are: high throughput genomic services and biomarker discovery, cytogenetics, single cell analysis, and licensing.

OGT’s genomic services (Genefficiency™) offer a unique combination of industry leading platforms, expert people and unparalleled sample processing power to rapidly deliver high quality genomic data to customers worldwide.

OGT’s products and services for cytogenetics (CytoSure™) include a range of high resolution oligonucleotide arrays, labelling kits and interpretation software that together provide a complete solution for the detection of chromosomal abnormalities.

Together, Genefficiency™ and CytoSure™ offer a unique, standardised and integrated solution for disease and cytogenetics research.

**For research use only**

This product is provided under an agreement between Agilent Technologies, Inc. and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents,



pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

For further information on OGT products and services please visit <http://www.ogt.co.uk/>

**- copy ends -**